Runimotamab

芦莫妥单抗

Report date: 2026/03/19 16:47:02

Base Information

Drug NameRunimotamab

Drug Alias NameBTRC-4017ARG-6194RO-7227780

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsT cell surface glycoprotein CD3 inhibitors

TargetsReceptor protein-tyrosine kinase erbB-2T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[14]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A